or Try an Advanced Search...

    Technical Analysis for ESPR - Esperion Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 2.13 -5.33% -0.12
    ESPR closed down 5.33 percent on Friday, May 24, 2024, on 58 percent of normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ESPR trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Fell Below 50 DMA Bearish -5.33%
    20 DMA Support Bullish -5.33%
    Wide Bands Range Expansion -5.33%
    Down 3 Days in a Row Weakness -5.33%
    Shooting Star Candlestick Bearish -10.50%
    New Uptrend Bullish -10.50%
    Older End-of-Day Signals for ESPR ...

       Recent Intraday Alerts

    Alert Time
    Down 5% 4 days ago
    60 Minute Opening Range Breakdown 4 days ago
    Down 3% 4 days ago
    Fell Below Previous Day's Low 4 days ago
    1.5x Volume Pace 4 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ESPR Chart by TradingView
    Basic chart:

    Profile

    Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin

    Is ESPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 23 Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
    May 23 Esperion to Participate in Upcoming June Investor Conferences
    May 22 First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
    May 20 Esperion's late stage trial of high cholesterol treatment met main goal
    May 20 Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
    May 20 Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
    May 14 Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
    May 10 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    May 8 Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
    May 8 Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
    See more ESPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.4
    52 Week Low 0.7
    Average Volume 8,320,223
    200-Day Moving Average 1.86
    50-Day Moving Average 2.30
    20-Day Moving Average 2.21
    10-Day Moving Average 2.33
    Average True Range 0.21
    RSI (14) 45.95
    ADX 24.41
    +DI 24.04
    -DI 17.34
    Chandelier Exit (Long, 3 ATRs) 2.00
    Chandelier Exit (Short, 3 ATRs) 2.51
    Upper Bollinger Bands 2.55
    Lower Bollinger Band 1.87
    Percent B (%b) 0.38
    BandWidth 30.72
    MACD Line 0.02
    MACD Signal Line 0.02
    MACD Histogram 0.0083
    Fundamentals Value
    Market Cap 381.11 Million
    Num Shares 179 Million
    EPS -2.27
    Price-to-Earnings (P/E) Ratio -0.94
    Price-to-Sales 4.49
    Price-to-Book 74.89
    PEG Ratio -4.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.36
    Resistance 3 (R3) 2.38 2.32 2.32
    Resistance 2 (R2) 2.32 2.26 2.31 2.31
    Resistance 1 (R1) 2.23 2.23 2.20 2.21 2.30
    Pivot Point 2.17 2.17 2.16 2.16 2.17
    Support 1 (S1) 2.07 2.11 2.05 2.05 1.96
    Support 2 (S2) 2.02 2.07 2.01 1.95
    Support 3 (S3) 1.92 2.02 1.94
    Support 4 (S4) 1.90